Allergan Continues Assault On Valeant Disclosure Policy
Allergan Inc. on Tuesday continued to criticize Valeant Pharmaceuticals International Inc. for a lack of transparency and an inconsistent disclosure policy, keeping up its attack on a $53 billion hostile bid...To view the full article, register now.
Already a subscriber? Click here to view full article